(Q37892583)

24 August 2017

1 reference

title

Vaccine-based clinical trials in ovarian cancer (English)

1 reference

24 August 2017

1 reference

2

Toos Daemen

1 reference

24 August 2017

Ninke Leffers

1

1 reference

24 August 2017

H Marike Boezen

series ordinal

3

1 reference

24 August 2017

Kees J M Melief

series ordinal

4

1 reference

24 August 2017

Hans W Nijman

series ordinal

5

1 reference

24 August 2017

publication date

1 June 2011

1 reference

Expert Review of Vaccines

24 August 2017

published in

1 reference

24 August 2017

volume

10

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

775-784

1 reference

Global cancer statistics, 2002

24 August 2017

cites work

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

21 January 2018

1 reference

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

21 January 2018

1 reference

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.

21 January 2018

1 reference

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

HER-2/neu as a target for cancer vaccines

21 January 2018

1 reference

Immunologic aspect of ovarian cancer and p53 as tumor antigen

21 January 2018

1 reference

Potential target antigens for a universal vaccine in epithelial ovarian cancer

21 January 2018

1 reference

Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines

21 January 2018

1 reference

MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma

21 January 2018

1 reference

Immunologic approaches to ovarian cancer treatment

21 January 2018

1 reference

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

Cellular immunotherapy for ovarian cancer

21 January 2018

1 reference

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

Whole tumor antigen vaccines

21 January 2018

1 reference

Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.

21 January 2018

1 reference

A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer

21 January 2018

1 reference

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer

21 January 2018

1 reference

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

21 January 2018

1 reference

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

21 January 2018

1 reference

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial

21 January 2018

1 reference

Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy

21 January 2018

1 reference

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

21 January 2018

1 reference

Taming cancer by inducing immunity via dendritic cells

21 January 2018

1 reference

Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients

21 January 2018

1 reference

Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition

21 January 2018

1 reference

Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens

21 January 2018

1 reference

Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma

21 January 2018

1 reference

Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer

21 January 2018

1 reference

Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes

21 January 2018

1 reference

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).

21 January 2018

1 reference

Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).

21 January 2018

1 reference

Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

21 January 2018

1 reference

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer

21 January 2018

1 reference

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer

21 January 2018

1 reference

The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.

21 January 2018

1 reference

Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).

21 January 2018

1 reference

A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer

21 January 2018

1 reference

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis

21 January 2018

1 reference

CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer

21 January 2018

1 reference

Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement

21 January 2018

1 reference

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation

21 January 2018

1 reference

Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force.

21 January 2018

1 reference

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 January 2018

1 reference

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours

21 January 2018

1 reference

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.

21 January 2018

1 reference

Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment

21 January 2018

1 reference

Targeted therapies to improve tumor immunotherapy

21 January 2018

1 reference

The tumor microenvironment and its role in promoting tumor growth

21 January 2018

1 reference

Angiogenesis as a strategic target for ovarian cancer therapy

21 January 2018

1 reference

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.11.42

1 reference

24 August 2017

1 reference